Continued Peer Reviewer Representation Consultant Speaker s Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Raymond F. Stainback Content Reviewer ACC Appropriate Use Criteria Task Force None None None None None None Eric Stecker Content Reviewer ACC Clinical Quality Committee None None None Biotronik Medtronic Boston Scientific None None James E. Tcheng Content Reviewer ACC/AHA Task Force on Data Standards None None None Philips Medical Systems None None Randal J. Thomas Organizational Reviewer AACVPR None None None None None None Thomas T. Tsai Content Reviewer ACC NCDR Science and Quality Oversight Committee None None None None None None Thad Waites Official Reviewer ACC Board of Trustees None None None None None None Tracy Y. Wang Content Reviewer ACC/AHA Task Force on Data Standards AstraZeneca Medco Health Solutions None None Bristol-Myers Squibb Canyon Pharmaceuticals Daiichi Sankyo Eli Lilly Heartscape Merck Sanofi-Aventis The Medicines Company Gilead None None Michael J. Wolk Content Reviewer ACC Appropriate Use Criteria Task Force None None None None None None This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $10 000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. 